Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 2, 2023 (3 years ago)

Bevacizumab 1.25 MG/0.05 ML Solution for Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Bevacizumab 1.25 MG/0.05 ML Solution for Injection, 1 mL syringes, Rx only, Compounded by Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150.

Drug: Bevacizumab

Recalling firm
Pine Pharmaceuticals, LLC
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0050-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bevacizumab recalls

See all
Class III · Low risk

Bevacizumab 2.5 mg/0.1 mL

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Terminated Labeling / mix-up Pine Pharmaceuticals, LLC NDC 69194-0458-1 D-0531-2023
Class II · Moderate risk

MVASI (bevacizumab-awwb)

Defective container: loose crimp defect, potential loss of container integrity.

Terminated Packaging defect Amgen, Inc. NDC 55513-0206-01 D-0855-2022

Other recalls by Pine Pharmaceuticals, LLC

All 2023 recalls